Reports of COVID-19 vaccinations causing blood clots has caused alarm in the general population. However due to the rarity of incidences from vaccination, myGP explores the most common causes of blood clots and how we can prevent them. Over 11 million doses of COVID-19 vaccines have been given across the UK, with blood clotting observed …
New recommendations may provide reassurance for patients and their care teams, while uniquely positioning healthcare providers to help communicate this critical information to vulnerable populations.
These next few months are a tremendous opportunity to build trust with customers — imagine the reciprocal goodwill if a payer’s message helps its members get to the front of the line.
With widespread vaccine shortages alongside continuing deaths from Covid-19, we must act now to leverage existing technology in order to improve the distribution process.
To counter vaccine hesitancy, especially dominant in at-risk communities, we need hyper-local and population-specific vaccine programs.
The vaccine is being delivered to 195 countries with different databases healthcare systems. Healthtech solutions help us bring together data from different healthcare organizations, manufacturing and distributing facilities, and government departments into a centralized location.
Covid vaccines are the talk of the town but in the meantime, there remains a great need for Covid-19 management solutions – including effective screening, efficient testing, improving treatments, battling vaccine misinformation, continued mask-wearing and social distancing – to protect the public.
The company, which got started in genomic testing, has quickly expanded its services to include providing Covid-19 testing at businesses and universities. With the new funding, it plans to build infrastructure for more preventive health services.
The CEO of Surescripts shares his predictions for the health IT segment that include policy and technology projections.
The company’s vaccine is the second approved for emergency use by the FDA. It is expected to pose fewer logistical challenges than the first, which was developed by Pfizer and BioNTech.